Silence Therapeutics (NASDAQ:SLN) Releases Quarterly Earnings Results

Silence Therapeutics (NASDAQ:SLN) announced its earnings results on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.07, Zacks reports. Silence Therapeutics had a negative return on equity of 93.20% and a negative net margin of 15,851.88%.The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $2.19 million.

Silence Therapeutics Stock Performance

Shares of NASDAQ SLN opened at $6.23 on Friday. Silence Therapeutics has a 52-week low of $1.97 and a 52-week high of $7.78. The firm has a market capitalization of $294.24 million, a price-to-earnings ratio of -3.33 and a beta of 1.32. The stock has a 50 day moving average price of $5.32 and a 200 day moving average price of $5.76.

Institutional Investors Weigh In On Silence Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Nantahala Capital Management LLC grew its position in shares of Silence Therapeutics by 48.0% during the 4th quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock worth $9,378,000 after buying an additional 500,000 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Silence Therapeutics by 121.0% in the fourth quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock valued at $4,010,000 after acquiring an additional 361,080 shares in the last quarter. UBS Group AG lifted its stake in Silence Therapeutics by 34.5% in the third quarter. UBS Group AG now owns 307,363 shares of the company’s stock worth $1,595,000 after acquiring an additional 78,854 shares during the period. Boothbay Fund Management LLC lifted its stake in Silence Therapeutics by 10.8% in the third quarter. Boothbay Fund Management LLC now owns 279,637 shares of the company’s stock worth $1,451,000 after acquiring an additional 27,216 shares during the period. Finally, Bank of Montreal Can grew its holdings in Silence Therapeutics by 4.4% during the 4th quarter. Bank of Montreal Can now owns 160,474 shares of the company’s stock worth $976,000 after acquiring an additional 6,692 shares in the last quarter. 98.73% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Thursday, January 22nd. Jefferies Financial Group reiterated a “buy” rating on shares of Silence Therapeutics in a research report on Thursday. Finally, Wall Street Zen raised shares of Silence Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Five research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $34.50.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.